Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
67 hedge funds and large institutions have $1.37B invested in Rubius Therapeutics, Inc in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 4 reducing their positions, and 5 closing their positions.
775% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 4
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
23% more capital invested
Capital invested by funds: $1.11B → $1.37B (+$256M)
18% more funds holding
Funds holding: 57 → 67 (+10)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.1M |
| 2 |
Janus Henderson Group
London,
|
+$12.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.8M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$7.94M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$7.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$457K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$60.5K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$27.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$22K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.97K |
RUBY Hedge Fund Activity: Q1 2019 in Review
67 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q1 2019, worth a combined $1.37B — up 23% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RUBY positions and 5 closed out — a net gain of 10 holders — while 35 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $17.1M. The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $457K sold.
- 67 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q1 2019, up from 57 in Q4 2018.
- Funds reported $1.37B of Rubius Therapeutics, Inc stock for Q1 2019, up 23% quarter-over-quarter.
- 15 funds opened new Rubius Therapeutics, Inc positions in Q1 2019 and 5 closed out, a net change of +10 holders.
- The largest Rubius Therapeutics, Inc buyer in Q1 2019 was Vanguard Group, an estimated $17.1M added.
- The largest Rubius Therapeutics, Inc seller in Q1 2019 was DekaBank Deutsche Girozentrale, an estimated $457K sold.
Based on aggregated 13F filings for Q1 2019.